Project Grant R03TR004017

Award Date 7/1/22
Completion Date 6/30/24
Dollars Obligated $235K
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This $1,073,982 National Cancer Institute project grant will fund research at Washington University in University City, Missouri from January 2023 through December 2027 under the Cancer Cause and Prevention Research program (CFDA 93.393). The research aims to document unmet social needs among 300 patient-caregiver dyads where the patient has breast or gynecologic cancer. It will analyze how social needs affect biopsychosocial outcomes for patients and caregivers, including depressive symptoms,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $197,640 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop implementation strategies to initiate colorectal cancer (CRC) screening in previously unscreened individuals aged 45 to 54 at a predominantly Black community health center in Boston, Massachusetts. The key objectives are to: (1) identify system-level determinants of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $635,035 to The Medical College of Wisconsin, Inc. to conduct the Self-Sampling to Optimize Anal Lesion Outcomes (SOLO) study. The objective is to use a randomized controlled trial to test the effect of self-sampling on attendance at cytology and high-resolution anoscopy (HRA) appointments for the early detection of squamous cell carcinoma of the anus (SCCA) among...
This federal Project Grant award of $622,913 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will fund a 5-year study to evaluate a multilevel intervention to increase colonoscopic follow-up after abnormal stool-based colorectal cancer screening in a community safety-net setting. The study will be conducted by the University of California, Los Angeles (UCLA) in partnership with the Northeast Valley Health Corporation (NEVHC), a...
The federal Project Grant award R01CA299475, titled "DEVELOPMENT OF SYSTEMS AND EDUCATION FOR CERVICAL CANCER PREVENTION (DOSE-CC)", is funded by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program) for $753,446. The grant aims to adapt and test an intervention to improve cervical cancer screening and follow-up in three diverse, underserved populations: urban inner city Blacks/Haitians, Hispanic immigrants, and Hawaiian natives/Pacific Islanders. The...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, aims to develop and evaluate an evidence-based, behavioral cervical cancer screening intervention for women living with HIV in Ghana. The $511,959 award to Baylor University will fund a hybrid effectiveness-implementation trial to integrate and scale up a home-based HPV self-sampling and communication model intervention called HOPE. The project seeks to...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $547,047.00 to Georgetown University to test the bundling of multicancer screening and genetic services navigation to improve cancer health equity among non-Hispanic Black and Hispanic women. The project aims to address patient- and organization-level barriers that limit cancer screening and genetic testing rates, which can contribute to disparities in breast and colorectal...
This Project Grant award from the Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes program (CFDA 93.226) supports a $400,000 randomized trial to evaluate the impact of a "whole person navigation" intervention for adults with multiple chronic conditions. The intervention combines predictive modeling to identify high-risk patients with a navigation strategy to help guide them in accessing social services and overcoming...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $192,610 to The University of Kentucky Research Foundation and its sub-awardee Augusta University Research Institute to conduct a study entitled "Pathways to Prevention: Exploring Social Determinants of Health in Early Onset Colorectal Cancer." The primary objective is to evaluate the impact of various social determinants of health (SDOH) factors on early-onset...
This $171,989 Project Grant awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) will support the University of Florida in adapting and evaluating the PINPOINT intervention to improve cervical cancer outcomes among women with chronic conditions and social vulnerability. The key products and services to be delivered under this five-year award include: 1) analyzing real-world health data to identify high-risk populations for cervical cancer, 2) using intervention...

EVALUATING THE IMPACT OF BASIC NEEDS ASSESSMENT AND SUPPORT TO IMPROVE COLPOSCOPY SHOW RATE: THE BASICS TRIAL - PROJECT SUMMARY/ABSTRACT EACH YEAR, APPROXIMATELY 3.5 MILLION INDIVIDUALS HAVE AN ABNORMAL CERVICAL SCREENING RESULT AND ARE RECOMMENDED FOR MEDICAL FOLLOW-UP, MOST COMMONLY COLPOSCOPY. COLPOSCOPY ALLOWS HEALTH PROVIDERS TO DETECT PRE-CANCERS AND OFFER THERAPEUTIC INTERVENTIONS THAT MAY PREVENT CERVICAL CANCER. UNFORTUNATELY, BETWEEN 37% AND 77% OF PATIENTS ARE LOST TO FOLLOW-UP AFTER THEIR ABNORMAL SCREEN AND NEVER RECEIVE APPROPRIATE CARE. LOW ADHERENCE TO COLPOSCOPY IS ESPECIALLY PREVALENT AMONG BLACK PATIENTS, THOSE WITH LOW INCOME, AND INDIVIDUALS WHO ARE UNINSURED OR HAVE MEDICAID, LEADING TO SOCIOECONOMIC DISPARITIES IN CERVICAL CANCER INCIDENCE AND MORTALITY. OUR PRELIMINARY DATA FROM TWO UNIVERSITY-BASED COLPOSCOPY CLINICS THAT PROVIDE CARE TO THESE UNDERSERVED PATIENTS, SHOW THAT COLPOSCOPY ADHERENCE IMPROVED FROM 50% TO 83% AFTER IMPLEMENTATION OF A TAILORED PHONE CALL INTERVENTION REMINDING PATIENTS OF THEIR APPOINTMENT AND OFFERING NAVIGATOR ASSISTANCE WITH UNMET SOCIAL NEEDS (E.G. UTILITIES, TRANSPORTATION, FOOD, SHELTER, CLOTHING, SAFETY). THESE PILOT DATA SUGGEST THAT A SOCIAL NEEDS NAVIGATOR PROGRAM IMPROVES COLPOSCOPY ADHERENCE, BUT THE LACK OF RANDOMIZATION LIMITS THE STRENGTH OF OUR CONCLUSIONS. IN THIS PROPOSAL, OUR OBJECTIVE IS TO TEST, AND ASSESS THE READINESS FOR IMPLEMENTATION OF A COLPOSCOPY CLINIC-BASED SOCIAL NEEDS NAVIGATOR PROGRAM FOCUSED ON FIVE SOCIAL DETERMINANTS OF HEALTH: HOUSING/SHELTER, FOOD INSECURITY, PERSONAL AND NEIGHBORHOOD SAFETY, FINANCIAL NEEDS, AND DISTRESS. THIS PROJECT WILL TEST THE HYPOTHESIS THAT THIS EQUITY-FOCUSED, SOCIAL NEEDS NAVIGATOR PROGRAM CAN IMPROVE COLPOSCOPY ADHERENCE AMONG UNDERSERVED PATIENTS. WE WILL PERFORM A RANDOMIZED CONTROLLED TRIAL IN WHICH 72 ELIGIBLE PATIENTS (LOW-INCOME, UNINSURED, OR ON MEDICAID) WHO ARE REFERRED FOR COLPOSCOPY AT WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, ARE ENROLLED AND THEN SCREENED FOR UNMET SOCIAL NEEDS AND DISTRESS. THEY WILL THEN BE RANDOMIZED 1:1 INTO EITHER RECEIVE THE SOCIAL NEEDS NAVIGATOR PROGRAM (N=36) OR ENHANCED USUAL CARE (N=36). IN THE NAVIGATOR ARM, A COMMUNITY HEALTH WORKER WILL PROVIDE FOUR MONTHS OF ASSISTANCE TAILORED TO THEIR NEEDS. IN THE ENHANCED USUAL CARE ARM, PATIENTS WILL BE OFFERED INFORMATION AND REFERRAL TO UNITED WAY 2-1-1, A FREE, 24-HR NATIONAL HELPLINE THAT CONNECTS CALLERS WITH LOCAL RESOURCES. IN SPECIFIC AIM 1 WE WILL DETERMINE THE EFFICACY OF OUR SOCIAL NEEDS NAVIGATOR PROGRAM TO IMPROVE COLPOSCOPY ADHERENCE. AIM 2 WILL ASSESS THE ABILITY OF OUR NAVIGATOR PROGRAM TO REDUCE UNMET SOCIAL NEEDS AND DISTRESS. AIM 3 WILL USE THE RE-AIM FRAMEWORK TO EVALUATE METRICS OF IMPLEMENTATION AND POTENTIAL FOR DISSEMINATION. THE PROPOSED WORK WILL PROVIDE KEY DATA TO LAUNCH A LARGE, PRAGMATIC, MULTISITE RANDOMIZED CONTROLLED TRIAL TO RIGOROUSLY TEST THE EFFECTIVENESS, IMPLEMENTATION, AND MAINTENANCE OF OUR SOCIAL NEEDS NAVIGATOR PROGRAM ACROSS DIFFERENT PATIENT POPULATIONS, COMMUNITY SETTINGS, AND HEALTHCARE ORGANIZATIONS. IF SUCH A TRIAL SHOWS THAT OUR NAVIGATOR PROGRAM IS EFFECTIVE, COST-EFFECTIVE, FEASIBLE, AND ACCEPTABLE, IT CAN BE WIDELY IMPLEMENTED TO IMPROVE COLPOSCOPY ADHERENCE AND EQUITY IN CERVICAL CANCER PREVENTION, INCIDENCE, AND MORTALITY.

Posted 7/1/22, 12:00 AM